Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Launched by NATIONAL CANCER INSTITUTE (NCI) · Dec 15, 2017
Trial Information
Current as of May 19, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a medication called cabozantinib to see how well it works for patients with advanced neuroendocrine tumors, including carcinoid tumors. These tumors can be found in various parts of the body and may have spread from their original location. Cabozantinib is designed to slow down tumor growth by targeting specific areas in the body that help tumors grow. In this trial, some participants will receive cabozantinib, while others will receive a placebo, which is a non-active treatment, so that researchers can compare the effects of both.
To participate in this study, patients must be at least 18 years old and have been diagnosed with specific types of neuroendocrine tumors that are either advanced and cannot be removed by surgery or have spread to other parts of the body. Participants should have measurable disease progression in the past year and have already tried at least one other treatment for their cancer. During the trial, participants will be closely monitored for any side effects and the effectiveness of the treatment. It's important to note that patients cannot be pregnant or nursing and should meet other health criteria to ensure their safety during the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Documentation of Disease:
- • Histologic Documentation: Well- or moderately-differentiated neuroendocrine tumors of pancreatic and non-pancreatic (i.e. carcinoid) origin by local pathology
- • The pathology report must state ONE of the following: 1) well- or moderately-differentiated neuroendocrine tumor, 2) low- or intermediate-grade neuroendocrine tumor, or 3) carcinoid tumor or atypical carcinoid tumor; documentation of histology from a primary or metastatic site is allowed
- • Patients with poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma without specification of differentiation status, adenocarcinoid tumor, or goblet cell carcinoid tumor are not eligible. Patients with well-differentiated grade 3 neuroendocrine tumor are eligible
- • Stage: Locally advanced/unresectable or metastatic disease
- • Tumor Site: Histological documentation of neuroendocrine tumor of pancreatic, gastrointestinal (GI), lung, thymus, other, or unknown primary site; GI, lung, thymus, other, and unknown primary NETs will enroll in the carcinoid tumor cohort of the study
- • Functional (i.e., associated with symptoms or clinical syndrome related to hormone secretion by tumor) or nonfunctional tumors are allowed
- • Radiologic Evaluation: Target lesions must have shown evidence of disease progression by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria in the 12 months prior to registration; the radiologic images, imaging reports, and clinic notes indicating growth of existing lesions, development of new lesions, or treatment changes must be submitted
- • Measurable Disease
- • Patients must have measurable disease per RECIST 1.1 by computer tomography (CT) scan or magnetic resonance imaging (MRI)
- • Lesions must be accurately measured in at least one dimension (longest diameter to be recorded) as \>= 1 cm with CT or MRI (or \>= 1.5 cm for lymph nodes); non-measurable disease includes disease smaller than these dimensions or lesions considered truly non-measurable including: leptomeningeal disease, ascites, pleural or pericardial effusion, lymphangitic involvement of skin or lung
- • Prior Treatment
- • Patient must have experienced disease progression after receiving or intolerance leading to treatment discontinuation of at least one Food and Drug Administration (FDA)-approved line of therapy (except somatostatin analogs); prior lines of therapy must include one of the following: everolimus, sunitinib, or lutetium Lu 177 dotatate in patients with pancreatic NET; everolimus in patients with lung NET; everolimus or lutetium Lu 177 dotatate in patients with gastrointestinal NET
- • Prior treatment (except somatostatin analogs) with biologic therapy, immunotherapy, chemotherapy, investigational agent for malignancy, and/or radiation must be completed at least 28 days prior to registration
- • Prior treatment with somatostatin analogs is allowed, and continuation of treatment with somatostatin analogs while on cabozantinib/placebo is allowed provided that the patient has been on a stable dose for at least two months
- • Prior systemic treatment with radionuclide therapy must be completed at least 6 weeks prior to registration
- • Prior treatment with hepatic artery embolization (including bland embolization, chemoembolization, and selective internal radiation therapy) or ablative therapies is allowed if measurable disease remains outside of the treated area or if there is documented disease progression in a treated site; prior liver-directed or other ablative treatment must be completed at least 28 days prior to registration
- • Prior treatment with cabozantinib is not allowed
- • Patients should have resolution of any toxic effects of prior therapy (except alopecia and fatigue) to National Cancer Institute (NCI) CTCAE, version 5.0, grade 1 or less
- • Patients must have completed any major surgery at least 12 weeks prior to registration and any minor surgery (including uncomplicated tooth extractions) at least 28 days prior to registration; complete wound healing from major surgery must have occurred at least 28 days prior to registration, and complete wound healing from minor surgery must have occurred at least 10 days prior to registration
- • Patient History
- • No class III or IV congestive heart failure (CHF) within 6 months of registration
- • No clinically significant cardiac arrhythmia within 6 months of registration
- • No unstable angina or myocardial infarction (MI) within 6 months of registration
- • No thromboembolic events within 6 months of registration (including \[incl.\] stroke, transient ischemic attack \[TIA\], deep vein thrombosis \[DVT\], \& pulmonary embolism \[PE\])
- • No known history of congenital long QT syndrome
- • No uncontrolled hypertension within 14 days of registration (defined as systolic blood pressure \[SBP\] \>= 150 mmHg and/or diastolic blood pressure \[DBP\] \>= 90 mmHg despite optimal medical management)
- • No clinically significant GI bleeding within 6 months of registration
- • No clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding within 6 months of registration including, but not limited to: active peptic ulcer, known endoluminal metastatic lesion(s) with history of bleeding, inflammatory bowel disease, or other gastrointestinal conditions with increased risk of perforation
- • No GI perforation within 6 months of registration
- • No known tumor with invasion into the GI tract from the outside causing increased risk of perforation or bleeding within 28 days of registration
- • No radiologic or clinical evidence of pancreatitis
- • No known cavitary lung lesions
- • No known endobronchial lesions involving the main or lobar bronchi and/or lesions infiltrating major pulmonary vessels that increase the risk of pulmonary hemorrhage; (CT with contrast is recommended to evaluate such lesions)
- • No hemoptysis greater than 1/2 teaspoon (2.5 mL) or any other signs of pulmonary hemorrhage within the 3 months prior to registration
- • No known tumor invading or encasing any major blood vessels
- • No history of non-healing wounds or ulcers within 28 days of registration
- • No history of fracture within 28 days of registration
- • No brain metastases or cranial epidural disease unless adequately treated, stable, and off steroid support for at least 4 weeks prior to registration
- • No known medical condition causing an inability to swallow oral formulations of agents
- • No history of allergic reaction attributed to compounds of similar chemical or biological composition to cabozantinib/placebo
- • No "currently active" second malignancy other than non-melanoma skin cancers or cervical carcinoma in situ; patients are not considered to have a "currently active" malignancy if they have completed therapy and are free of disease for \>= 3 years
- • Concomitant Medications
- • Other planned concurrent investigational agents or other tumor directed therapies (chemotherapy, radiation) are not allowed while on this study
- • Concurrent use of somatostatin analogs while on cabozantinib/placebo is allowed provided that the patient has been on a stable dose for at least two months
- • Full dose oral anticoagulation/antiplatelet therapy is not permitted; low dose aspirin =\< 81 mg/day is allowed; anticoagulation with therapeutic doses of low molecular weight heparin (LMWH) is allowed in patients who are on a stable dose of LMWH for at least 6 weeks prior to registration; treatment with warfarin is not allowed; anticoagulation in patients with brain metastases is not permitted
- • Chronic concomitant treatment with strong inhibitors of CYP3A4 is not allowed; patients must discontinue the drug at least 14 days prior to registration on the study
- • Chronic concomitant treatment with strong CYP3A4 inducers is not allowed; patients must discontinue the drug at least 14 days prior to registration on the study
- • Not pregnant and not nursing
- • Women of childbearing potential must have a negative pregnancy test done =\< 14 days prior to registration
- • A female of childbearing potential is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 12 consecutive months (i.e. has had menses at any time in the preceding 12 consecutive months)
- • Age \>= 18 years
- • Eastern Cooperative Oncology Group (ECOG) performance status: 0-2
- • Absolute neutrophil count (ANC) \>= 1,500/mm\^3
- • Hemoglobin \>= 9 g/dL
- • Platelet count \>= 100,000/mm\^3
- • Prothrombin time (PT)/ international normalized ratio (INR), partial thromboplastin time (PTT) \< 1.3 x upper limit of normal (ULN)
- • Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) =\< 3 x ULN
- • Total bilirubin =\< 1.5 x ULN
- • Except in the case of Gilbert disease, in which case total bilirubin must be =\< 3 x ULN
- • Creatinine =\< 1.5 mg/dL OR creatinine clearance \>= 45 mL/min
- • Albumin \>= 2.8 g/dL
- • Potassium within normal limits (WNL)
- • Supplementation is acceptable to achieve a value WNL; in patients with low albumin levels, a corrected calcium value WNL is acceptable; in patients with abnormal thyroid stimulating hormone (TSH), if free T4 is normal and patient is clinically euthyroid, patient is eligible
- • Phosphorus WNL
- • Supplementation is acceptable to achieve a value WNL; in patients with low albumin levels, a corrected calcium value WNL is acceptable; in patients with abnormal TSH, if free T4 is normal and patient is clinically euthyroid, patient is eligible
- • Calcium WNL
- • Supplementation is acceptable to achieve a value WNL; in patients with low albumin levels, a corrected calcium value WNL is acceptable; in patients with abnormal TSH, if free T4 is normal and patient is clinically euthyroid, patient is eligible
- • Magnesium WNL
- • Supplementation is acceptable to achieve a value WNL; in patients with low albumin levels, a corrected calcium value WNL is acceptable; in patients with abnormal TSH, if free T4 is normal and patient is clinically euthyroid, patient is eligible
- • Urine protein to creatinine (UPC) ratio =\< 1
- • QT interval corrected for heart rate using Fridericia's formula (QTcF) =\< 500 msec
- • TSH WNL
- • Supplementation is acceptable to achieve a value WNL; in patients with low albumin levels, a corrected calcium value WNL is acceptable; in patients with abnormal TSH, if free T4 is normal and patient is clinically euthyroid, patient is eligible
About National Cancer Institute (Nci)
The National Cancer Institute (NCI) is a prominent component of the National Institutes of Health (NIH), dedicated to advancing cancer research and improving patient outcomes through innovative clinical trials. As a leading sponsor of cancer-related studies, NCI focuses on facilitating the development of new therapies, enhancing prevention strategies, and understanding the biology of cancer. The institute collaborates with academic institutions, healthcare providers, and industry partners to conduct rigorous clinical trials that aim to translate scientific discoveries into effective treatments. NCI’s commitment to fostering a robust research environment supports the mission to eliminate cancer as a major health problem.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lebanon, New Hampshire, United States
Cleveland, Ohio, United States
Boston, Massachusetts, United States
New York, New York, United States
Buffalo, New York, United States
Saint Louis, Missouri, United States
Philadelphia, Pennsylvania, United States
Boston, Massachusetts, United States
Flint, Michigan, United States
Kalamazoo, Michigan, United States
Burnsville, Minnesota, United States
Edina, Minnesota, United States
Waconia, Minnesota, United States
Maywood, Illinois, United States
South Bend, Indiana, United States
Baton Rouge, Louisiana, United States
Detroit, Michigan, United States
Little Rock, Arkansas, United States
Boston, Massachusetts, United States
Oklahoma City, Oklahoma, United States
Duarte, California, United States
Des Moines, Iowa, United States
Great Falls, Montana, United States
Ridgewood, New Jersey, United States
Saint Paul, Minnesota, United States
Greeley, Colorado, United States
Loveland, Colorado, United States
Ann Arbor, Michigan, United States
Kalamazoo, Michigan, United States
Bozeman, Montana, United States
Kalispell, Montana, United States
Sheridan, Wyoming, United States
Las Vegas, Nevada, United States
Oakland, California, United States
Chillicothe, Ohio, United States
Gresham, Oregon, United States
Tualatin, Oregon, United States
Coon Rapids, Minnesota, United States
Urbana, Illinois, United States
Ann Arbor, Michigan, United States
Minneapolis, Minnesota, United States
Saint Paul, Minnesota, United States
Shakopee, Minnesota, United States
Willmar, Minnesota, United States
Flint, Michigan, United States
Dayton, Ohio, United States
Effingham, Illinois, United States
Bethlehem, Pennsylvania, United States
Springfield, Illinois, United States
Philadelphia, Pennsylvania, United States
Portland, Oregon, United States
Roseville, California, United States
Englewood, New Jersey, United States
Pittsburgh, Pennsylvania, United States
Tampa, Florida, United States
Boston, Massachusetts, United States
Honolulu, Hawaii, United States
Minneapolis, Minnesota, United States
Rochester, New York, United States
Philadelphia, Pennsylvania, United States
Salt Lake City, Utah, United States
Aurora, Colorado, United States
Tucson, Arizona, United States
Modesto, California, United States
Palo Alto, California, United States
Sacramento, California, United States
Salinas, California, United States
Washington, District Of Columbia, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Iowa City, Iowa, United States
Detroit, Michigan, United States
Duluth, Minnesota, United States
Saint Louis, Missouri, United States
New York, New York, United States
Chapel Hill, North Carolina, United States
Bismarck, North Dakota, United States
Fargo, North Dakota, United States
Columbus, Ohio, United States
Pittsburgh, Pennsylvania, United States
Seattle, Washington, United States
Jacksonville, Florida, United States
Lexington, Kentucky, United States
Tulsa, Oklahoma, United States
Allentown, Pennsylvania, United States
Morgantown, West Virginia, United States
Cape Girardeau, Missouri, United States
Martinez, California, United States
Englewood, Colorado, United States
Fridley, Minnesota, United States
Robbinsdale, Minnesota, United States
Saint Louis Park, Minnesota, United States
Omaha, Nebraska, United States
Oakland, California, United States
Hollywood, Florida, United States
Albuquerque, New Mexico, United States
Sioux Falls, South Dakota, United States
Sacramento, California, United States
San Francisco, California, United States
Detroit, Michigan, United States
Rochester, Minnesota, United States
Madison, Wisconsin, United States
Marshfield, Wisconsin, United States
Honolulu, Hawaii, United States
Portland, Oregon, United States
Reno, Nevada, United States
Albuquerque, New Mexico, United States
Ottawa, Illinois, United States
Peoria, Illinois, United States
Butte, Montana, United States
Helena, Montana, United States
Cedar Rapids, Iowa, United States
Cedar Rapids, Iowa, United States
Clive, Iowa, United States
Des Moines, Iowa, United States
Des Moines, Iowa, United States
Lansing, Michigan, United States
Warren, Michigan, United States
Des Moines, Iowa, United States
Adrian, Michigan, United States
Monroe, Michigan, United States
Pontiac, Michigan, United States
Maplewood, Minnesota, United States
Maplewood, Minnesota, United States
Stillwater, Minnesota, United States
Great Falls, Montana, United States
Maumee, Ohio, United States
Maumee, Ohio, United States
Toledo, Ohio, United States
Fremont, California, United States
Redwood City, California, United States
Richmond, California, United States
Roseville, California, United States
Sacramento, California, United States
San Francisco, California, United States
San Jose, California, United States
San Leandro, California, United States
San Rafael, California, United States
Santa Clara, California, United States
Santa Rosa, California, United States
South San Francisco, California, United States
Stockton, California, United States
Vallejo, California, United States
Walnut Creek, California, United States
Atlanta, Georgia, United States
'Aiea, Hawaii, United States
Honolulu, Hawaii, United States
Honolulu, Hawaii, United States
Galesburg, Illinois, United States
Bettendorf, Iowa, United States
Battle Creek, Michigan, United States
Petoskey, Michigan, United States
Port Huron, Michigan, United States
Saginaw, Michigan, United States
Bemidji, Minnesota, United States
Woodbury, Minnesota, United States
Billings, Montana, United States
Billings, Montana, United States
Missoula, Montana, United States
Reno, Nevada, United States
Kinston, North Carolina, United States
Dayton, Ohio, United States
Franklin, Ohio, United States
Mentor, Ohio, United States
Toledo, Ohio, United States
Troy, Ohio, United States
Portland, Oregon, United States
East Stroudsburg, Pennsylvania, United States
Sioux Falls, South Dakota, United States
Minocqua, Wisconsin, United States
Oconomowoc, Wisconsin, United States
Rice Lake, Wisconsin, United States
Waukesha, Wisconsin, United States
Weston, Wisconsin, United States
Berkeley, California, United States
Mountain View, California, United States
Palo Alto, California, United States
San Francisco, California, United States
Colorado Springs, Colorado, United States
Denver, Colorado, United States
Wheat Ridge, Colorado, United States
Norwalk, Connecticut, United States
Burlington, Massachusetts, United States
Albuquerque, New Mexico, United States
Columbus, Ohio, United States
Columbus, Ohio, United States
Marietta, Ohio, United States
Newark, Ohio, United States
Zanesville, Ohio, United States
Huntington, West Virginia, United States
Livonia, Michigan, United States
East Syracuse, New York, United States
Mansfield, Ohio, United States
Newberg, Oregon, United States
New Ulm, Minnesota, United States
Albuquerque, New Mexico, United States
Boise, Idaho, United States
Denver, Colorado, United States
Marysville, California, United States
Danbury, Connecticut, United States
Hendersonville, North Carolina, United States
Tucson, Arizona, United States
Las Vegas, Nevada, United States
Honolulu, Hawaii, United States
Grand Junction, Colorado, United States
Council Bluffs, Iowa, United States
Goldsboro, North Carolina, United States
Canton, Illinois, United States
Carthage, Illinois, United States
Eureka, Illinois, United States
Kewanee, Illinois, United States
Macomb, Illinois, United States
Peru, Illinois, United States
Princeton, Illinois, United States
Boise, Idaho, United States
Appleton, Wisconsin, United States
Greenville, South Carolina, United States
Grand Island, Nebraska, United States
Burlingame, California, United States
Vallejo, California, United States
Post Falls, Idaho, United States
Bloomington, Illinois, United States
Pekin, Illinois, United States
Flint, Michigan, United States
Lansing, Michigan, United States
Mount Clemens, Michigan, United States
Washington, North Carolina, United States
Boiling Springs, South Carolina, United States
Easley, South Carolina, United States
Greenville, South Carolina, United States
Greenville, South Carolina, United States
Greer, South Carolina, United States
Seneca, South Carolina, United States
Arroyo Grande, California, United States
Vacaville, California, United States
Saint Louis, Missouri, United States
Erie, Pennsylvania, United States
Antioch, California, United States
Emeryville, California, United States
Fresno, California, United States
Modesto, California, United States
Sunnyvale, California, United States
Atlanta, Georgia, United States
Fruitland, Idaho, United States
Meridian, Idaho, United States
Nampa, Idaho, United States
Twin Falls, Idaho, United States
Clarkston, Michigan, United States
Flint, Michigan, United States
Beachwood, Ohio, United States
Columbus, Ohio, United States
Middleburg Heights, Ohio, United States
Parma, Ohio, United States
Portsmouth, Ohio, United States
Monroeville, Pennsylvania, United States
Vancouver, Washington, United States
New Richmond, Wisconsin, United States
Springfield, Illinois, United States
Belpre, Ohio, United States
Columbus, Ohio, United States
Delaware, Ohio, United States
Las Vegas, Nevada, United States
Saint Peters, Missouri, United States
Great Falls, Montana, United States
Auburn, California, United States
Santa Cruz, California, United States
Caldwell, Idaho, United States
Coeur D'alene, Idaho, United States
Emmett, Idaho, United States
Meridian, Idaho, United States
Nampa, Idaho, United States
Sandpoint, Idaho, United States
Clive, Iowa, United States
West Des Moines, Iowa, United States
Brighton, Michigan, United States
Canton, Michigan, United States
Caro, Michigan, United States
Chelsea, Michigan, United States
Clarkston, Michigan, United States
Clarkston, Michigan, United States
East China Township, Michigan, United States
Farmington Hills, Michigan, United States
Flint, Michigan, United States
Flint, Michigan, United States
Grosse Pointe Woods, Michigan, United States
Grosse Pointe Woods, Michigan, United States
Grosse Pointe Woods, Michigan, United States
Livonia, Michigan, United States
Macomb, Michigan, United States
Macomb, Michigan, United States
Marlette, Michigan, United States
Pontiac, Michigan, United States
Pontiac, Michigan, United States
Pontiac, Michigan, United States
Rochester Hills, Michigan, United States
Saginaw, Michigan, United States
Sterling Heights, Michigan, United States
Warren, Michigan, United States
Warren, Michigan, United States
Warren, Michigan, United States
Warren, Michigan, United States
West Branch, Michigan, United States
Ypsilanti, Michigan, United States
Minneapolis, Minnesota, United States
Anaconda, Montana, United States
Henderson, Nevada, United States
Henderson, Nevada, United States
Henderson, Nevada, United States
Henderson, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Paramus, New Jersey, United States
Clinton, North Carolina, United States
Jacksonville, North Carolina, United States
Centerville, Ohio, United States
Marion, Ohio, United States
Wadsworth, Ohio, United States
Baker City, Oregon, United States
Ontario, Oregon, United States
Cody, Wyoming, United States
Anchorage, Alaska, United States
Creston, Iowa, United States
Commack, New York, United States
Boulder, Colorado, United States
Denver, Colorado, United States
Englewood, Colorado, United States
Littleton, Colorado, United States
Lone Tree, Colorado, United States
Danville, Illinois, United States
Decatur, Illinois, United States
Effingham, Illinois, United States
Mattoon, Illinois, United States
New Lenox, Illinois, United States
O'fallon, Illinois, United States
Brighton, Michigan, United States
Canton, Michigan, United States
Chelsea, Michigan, United States
Ypsilanti, Michigan, United States
Maple Grove, Minnesota, United States
Wyoming, Minnesota, United States
Bonne Terre, Missouri, United States
Sainte Genevieve, Missouri, United States
Sullivan, Missouri, United States
Sunset Hills, Missouri, United States
Clackamas, Oregon, United States
Montvale, New Jersey, United States
Harrison, New York, United States
Uniondale, New York, United States
Middletown, New Jersey, United States
Dublin, California, United States
Henderson, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Auburn, New York, United States
Syracuse, New York, United States
Basking Ridge, New Jersey, United States
Sacramento, California, United States
San Rafael, California, United States
Denver, Colorado, United States
Baton Rouge, Louisiana, United States
Baton Rouge, Louisiana, United States
Baton Rouge, Louisiana, United States
Covington, Louisiana, United States
Houma, Louisiana, United States
Creve Coeur, Missouri, United States
Saint Louis, Missouri, United States
Carson City, Nevada, United States
Henderson, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Reno, Nevada, United States
Eau Claire, Wisconsin, United States
Council Bluffs, Iowa, United States
Fremont, California, United States
Wexford, Pennsylvania, United States
Farmington, Utah, United States
Mukwonago, Wisconsin, United States
Waukesha, Wisconsin, United States
Des Moines, Iowa, United States
Westlake, Ohio, United States
Phoenix, Arizona, United States
Orland Park, Illinois, United States
Jefferson Hills, Pennsylvania, United States
Tawas City, Michigan, United States
Las Vegas, Nevada, United States
Rio Rancho, New Mexico, United States
Perrysburg, Ohio, United States
Mount Pleasant, Michigan, United States
Henderson, Nevada, United States
Las Vegas, Nevada, United States
Pahrump, Nevada, United States
Stevens Point, Wisconsin, United States
Deer River, Minnesota, United States
Hibbing, Minnesota, United States
Sandstone, Minnesota, United States
Virginia, Minnesota, United States
Hazleton, Pennsylvania, United States
Ashland, Wisconsin, United States
Port Huron, Michigan, United States
Honolulu, Hawaii, United States
Golden, Colorado, United States
Lafayette, Colorado, United States
Thornton, Colorado, United States
Fort Dodge, Iowa, United States
Port Huron, Michigan, United States
'Aiea, Hawaii, United States
Wayne, New Jersey, United States
Kingman, Arizona, United States
Fort Myers, Florida, United States
Dixon, Illinois, United States
Washington, Illinois, United States
Baton Rouge, Louisiana, United States
Farmington, Missouri, United States
Las Vegas, Nevada, United States
San Mateo, California, United States
Burnsville, Minnesota, United States
Salt Lake City, Utah, United States
Bozeman, Montana, United States
Baton Rouge, Louisiana, United States
Council Bluffs, Iowa, United States
Kalamazoo, Michigan, United States
Omaha, Nebraska, United States
Omaha, Nebraska, United States
Paramus, New Jersey, United States
Missoula, Montana, United States
Aventura, Florida, United States
Aventura, Florida, United States
Boca Raton, Florida, United States
Fargo, North Dakota, United States
Greeley, Colorado, United States
'Aiea, Hawaii, United States
Nampa, Idaho, United States
Grand Island, Nebraska, United States
Perrysburg, Ohio, United States
Des Moines, Iowa, United States
Kalispell, Montana, United States
Lebanon, New Hampshire, United States
Nashua, New Hampshire, United States
Nampa, Idaho, United States
Pontiac, Michigan, United States
Ann Arbor, Michigan, United States
Brighton, Michigan, United States
Chelsea, Michigan, United States
Dayton, Ohio, United States
Webster, New York, United States
Danville, Illinois, United States
Canton, Michigan, United States
Minocqua, Wisconsin, United States
Sunset Hills, Missouri, United States
Des Moines, Iowa, United States
Clive, Iowa, United States
Lansing, Michigan, United States
Loveland, Colorado, United States
Pontiac, Michigan, United States
Madison, Wisconsin, United States
Kinston, North Carolina, United States
Ridgewood, New Jersey, United States
Washington, North Carolina, United States
Dayton, Ohio, United States
Sandpoint, Idaho, United States
Baker City, Oregon, United States
Ontario, Oregon, United States
Saginaw, Michigan, United States
Tawas City, Michigan, United States
Camillus, New York, United States
Wheat Ridge, Colorado, United States
Lafayette, Colorado, United States
Detroit, Michigan, United States
Grosse Pointe Woods, Michigan, United States
Grosse Pointe Woods, Michigan, United States
Macomb, Michigan, United States
Warren, Michigan, United States
Flint, Michigan, United States
Warren, Michigan, United States
East China Township, Michigan, United States
Macomb, Michigan, United States
Warren, Michigan, United States
Denver, Colorado, United States
Grosse Pointe Woods, Michigan, United States
Rochester Hills, Michigan, United States
Clive, Iowa, United States
Des Moines, Iowa, United States
Des Moines, Iowa, United States
Patients applied
Trial Officials
Jennifer A Chan
Principal Investigator
Alliance for Clinical Trials in Oncology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials